The Successful Outcome
- Developed a value story proactively addressing payer concerns around a third-to-market gene therapy
- Recommended strategies and communication points to effectively differentiate the GT form the competition, to give stakeholders a “reason to wait”
- Develop pragmatic and feasible recommendations for the phase III clinical trial design and feasible evidence collection strategies
![](https://partners4access.com/wp-content/uploads/2023/09/cs-gt-7-1024x604.png)